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Rapid urine-based screening for tuberculosis in HIV-positive 
patients admitted to hospital in Africa (STAMP): 
a pragmatic, multicentre, parallel-group, double-blind, 
randomised controlled trial
Ankur Gupta-Wright, Elizabeth L Corbett, Joep J van Oosterhout, Douglas Wilson, Daniel Grint, Melanie Alufandika-Moyo, Jurgens A Peters, 
Lingstone Chiume, Clare Flach, Stephen D Lawn*, Katherine Fielding
Summary
Background Current diagnostics for HIV-associated tuberculosis are suboptimal, with missed diagnoses contributing 
to high hospital mortality and approximately 374 000 annual HIV-positive deaths globally. Urine-based assays have a 
good diagnostic yield; therefore, we aimed to assess whether urine-based screening in HIV-positive inpatients for 
tuberculosis improved outcomes.
Methods We did a pragmatic, multicentre, double-blind, randomised controlled trial in two hospitals in Malawi and 
South Africa. We included HIV-positive medical inpatients aged 18 years or more who were not taking tuberculosis 
treatment. We randomly assigned patients (1:1), using a computer-generated list of random block size stratified by 
site, to either the standard-of-care or the intervention screening group, irrespective of symptoms or clinical 
presentation. Attending clinicians made decisions about care; and patients, clinicians, and the study team were 
masked to the group allocation. In both groups, sputum was tested using the Xpert MTB/RIF assay (Xpert; Cepheid, 
Sunnyvale, CA, USA). In the standard-of-care group, urine samples were not tested for tuberculosis. In the 
intervention group, urine was tested with the Alere Determine TB-LAM Ag (TB-LAM; Alere, Waltham, MA, USA), 
and Xpert assays. The primary outcome was all-cause 56-day mortality. Subgroup analyses for the primary outcome 
were prespecified based on baseline CD4 count, haemoglobin, clinical suspicion for tuberculosis; and by study site 
and calendar time. We used an intention-to-treat principle for our analyses. This trial is registered with the ISRCTN 
registry, number ISRCTN71603869.
Findings Between Oct 26, 2015, and Sept 19, 2017, we screened 4788 HIV-positive adults, of which 2600 (54%) were 
randomly assigned to the study groups (n=1300 for each group). 13 patients were excluded after randomisation from 
analysis in each group, leaving 2574 in the final intention-to-treat analysis (n=1287 in each group). At admission, 
1861 patients were taking antiretroviral therapy and median CD4 count was 227 cells per µL (IQR 79–436). Mortality 
at 56 days was reported for 272 (21%) of 1287 patients in the standard-of-care group and 235 (18%) of 1287 in the 
intervention group (adjusted risk reduction [aRD]  –2·8%, 95% CI –5·8 to 0·3; p=0·074). In three of the 12 prespecified, 
but underpowered subgroups, mortality was lower in the intervention group than in the standard-of-care group for 
CD4 counts less than 100 cells per μL (aRD –7·1%, 95% CI –13·7 to –0·4; p=0.036), severe anaemia (–9·0%, –16·6 to 
–1·3; p=0·021), and patients with clinically suspected tuberculosis (–5·7%, –10·9 to –0·5; p=0·033); with no difference 
by site or calendar period. Adverse events were similar in both groups.
Interpretation Urine-based tuberculosis screening did not reduce overall mortality in all HIV-positive inpatients, but 
might benefit some high-risk subgroups. Implementation could contribute towards global targets to reduce 
tuberculosis mortality.
Funding Joint Global Health Trials Scheme of the Medical Research Council, the UK Department for International 
Development, and the Wellcome Trust.
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Introduction
Tuberculosis remains the single major cause of mortality 
in patients with HIV globally, accounting for an estimated 
374 000 deaths in 2016.1 In many parts of sub-Saharan 
Africa, most admitted medical inpatients are HIV-positive 
and tuberculosis is the major cause of both admission 
(18–29%) and in-hospital death (21–33% in cohort studies 
and 32–67% in autopsy studies).2,3
Suboptimal diagnostics are an important contributor 
to poor outcomes from HIV-associated tuberculosis. 
Tuberculosis is commonly disseminated, presents with 
non-specific clinical features, and is only diagnosed 
Articles
www.thelancet.com   Vol 392   July 28, 2018 293
Correspondence to: 
Dr Ankur Gupta-Wright, 
Department of Clinical Research, 
Faculty of Infectious and Tropical 
Diseases, London School of 
Hygiene & Tropical Medicine, 
London WC1E 7HT, UK 
ankur.gupta-wright@
lshtm.ac.uk
before death in half of cases with a fatal outcome.3,4 
Mycobacterial culture, the current gold standard, is too 
centralised and slow to be clinically useful. Both culture 
and chest radiography are often unavailable in many 
African settings. The Xpert MTB/RIF assay provides 
robust and rapid detection of Mycobacterium tuberculosis 
nucleic acids from sputum and has been widely scaled-
up and decentralised, but patients with HIV-associated 
tuberculosis tend to have relatively low mycobacterial 
concentrations in pulmonary secretions and difficulty 
expectorating.5 Despite improved sensitivity (79% in 
patients with HIV),6 randomised trials comparing 
clinical outcomes between sputum Xpert MTB/RIF 
and microscopy have largely shown scant effect because 
of empiric tuberculosis therapy, other than systematic 
screening in HIV-positive outpatients with advanced 
disease.7,8
Urine can be readily obtained from patients admitted 
to hospital and is suitable for rapid tuberculosis diagnosis 
using either a lateral flow assay for lipoarabinomannan 
(LAM; a mycobacterial cell wall glycolipid) or Xpert 
MTB/RIF. Although urine is not a sample recom-
mended by WHO for Xpert, studies report high 
specificity for tuberculosis in HIV-positive patients.9,10 
Diagnosis using urinary LAM, reflecting frequent renal 
involvement from disseminated HIV-associated tubercu-
losis, is comple mentary to sputum testing, and identifies 
a subgroup of patients with poor prognosis.11,12 Current 
commercial LAM kits have a specificity of 98% or more 
and sensitivity of 40–70% in HIV–tuberculosis-coinfected 
patients with CD4 counts less than 100 cells per μL.13–15 
Combined testing with urine LAM, plus urine and 
sputum Xpert, can rapidly diagnose about 80% of all 
culture-positive tuberculosis in unselected HIV-positive 
admissions to medical wards in high HIV burden 
settings.15,16
Urine-based screening might provide more complete, 
timely, and potentially life-saving diagnosis of tubercu-
losis among HIV-positive hospital inpatients.7 We, 
therefore, aimed to investigate the effect of adding urine 
to sputum tuberculosis screening on early mortality, and 
its effect on diagnosis and treatment of tuberculosis in 
unselected HIV-positive hospital admissions.
Methods
Study design and patients
We did a pragmatic, multicentre, parallel-group, double-
blind, randomised controlled trial. We enrolled patients 
Research in context
Evidence before the study
We searched MEDLINE for studies that investigated the effect of 
urine lipoarabinomannan assay (LAM) or Xpert MTB/RIF assay 
(Xpert) on mortality or tuberculosis diagnosis in HIV-positive 
patients published from Jan 1, 2000, to Sept 30, 2016. We 
combined search terms for LAM (“lipoarabinomannan”, “LAM”, 
“TB LAM”, or “urine LAM”) or Xpert (“urine Xpert” or “urinary 
Xpert”) with HIV (“HIV”, “HIV-1”, “AIDS”, or “human 
immunodeficiency virus”) and mortality (“mortality”, “adult 
mortality”, or “death”), or tuberculosis diagnosis or screening 
(“diagnosis”, “diagnostic”, or “screening”). We identified 
14 observational studies, mostly done in antiretroviral therapy 
naive outpatients or hospital inpatients, which assessed the 
diagnostic accuracy of urine LAM or Xpert for tuberculosis or their 
association with mortality, or both. These studies showed 
moderate-to-good diagnostic yield of urinary assays in patients 
with advanced immunosuppression and in hospital inpatients, 
and an association with higher disease severity, poor prognosis, 
and mortality. Since undertaking our trial, one randomised trial 
has assessed adjunctive urine LAM testing in HIV-positive 
inpatients suspected of tuberculosis and found a reduction in 
8-week mortality. However, whether systematic urine-based 
screening for tuberculosis (using urine LAM and Xpert) for all 
HIV-positive hospital inpatients (irrespective of tuberculosis 
symptoms) could reduce mortality compared with sputum 
tuberculosis testing remained unclear.
Added value of this study
The findings from this randomised trial suggest that 
urine-based tuberculosis screening of HIV-positive hospital 
inpatients might reduce 56-day mortality in defined clinical 
subgroups (low CD4 count, severe anaemia, or clinically 
suspected tuberculosis). Moreover, wider application 
(screening all HIV-positive inpatients) could substantially 
reduce the risk of being discharged from hospital with 
undiagnosed tuberculosis in all patient groups. The major 
incremental diagnostic benefit was from urine LAM.
Implications of all the available evidence
These data support implementation of urine LAM-based 
screening of all HIV-positive inpatients for tuberculosis in 
hospitals in high HIV and tuberculosis burden settings, 
because the reliance on a combination of sputum-based 
diagnosis and clinically guided empirical treatment left 
patients at unacceptably high risk of discharge and death 
from undiagnosed tuberculosis. Collectively, current evidence 
supports international policy change to scale-up and broaden 
the use of urine-LAM testing in patients admitted to hospital 
(currently only recommended as an additional diagnostic in 
inpatients with symptoms of tuberculosis and CD4 counts 
<100 cells per µL or danger signs). Incremental gain was too 
limited to support urine Xpert. Because screening efficiency is 
dependent on prevalence, these results cannot be 
extrapolated to outpatients. Urine LAM screening could 
contribute towards reducing mortality and morbidity from 
HIV-associated tuberculosis and meeting global targets for 
tuberculosis mortality reduction.
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See Online for appendix
who were admitted to medical wards at Zomba Central 
Hospital in Malawi (a district and referral hospital 
covering urban and rural populations) and Edendale 
Hospital in South Africa (a large referral hospital 
covering a mostly urban population), irrespective of 
tuberculosis symptoms or admitting presentation. The 
study design has been previously described in detail,17 
and additional methods are provided in the appendix. 
We obtained ethical approval from the relevant 
committees in Malawi, South Africa, and from the trial 
sponsor in the UK, and the study was approved by 
the relevant national regulatory bodies (appendix). 
Deviations from the study protocol are described in the 
appendix.
All admissions to the medical wards were screened for 
eligibility by study nurses or clinicians. Screening 
occurred during office hours on weekdays, with patients 
enrolled as close to admission as possible. All patients 
with an unknown HIV status were offered point-of-care 
rapid HIV testing as per local guidelines (appendix). We 
included patients that were HIV positive and aged 18 years 
or older. We excluded those that were currently taking 
tuberculosis treatment, had been treated for tuberculosis 
in the preceding 12 months, taken isoniazid preventive 
therapy in the preceding 6 months, were unable or 
unwilling to provide informed consent, had been admitted 
to hospital for longer than 48 h at the time of screening, or 
lived outside the predefined hospital catchment area 
(appendix). We obtained written informed consent from 
all eligible patients.
Randomisation and masking
We randomly assigned eligible patients on enrolment 
(1:1) to either the standard-of-care tuberculosis screening 
group or the intervention screening group. Randomisation 
was stratified by site and a randomisation list of unique 
patient identifiers was generated by the study statistician 
using a computer-generated random block size. On 
enrolment, study nurses or clinicians took a consecutive 
sealed opaque envelope containing the unique patient 
identifier but not the study group, to which they remained 
masked. A paired set of sealed envelopes were kept in a 
locked cabinet in the study laboratory, labelled with the 
unique patient identifier and containing the study group 
allocation. These were opened by the laboratory 
technician on receipt of study tuberculosis screening 
specimens. Investigators, all study staff (other than the 
laboratory technician and statistician), hospital attending 
clinical teams, and patients were masked to the study 
group allocation.
Procedures
Following enrolment, 50 mL of urine and a single, 
spontaneously expectorated sputum sample were 
collected by the study team for tuberculosis screening. 
Failure to produce a specimen was not an exclusion 
criterion. The patient’s attending clinical team had the 
option of sending additional samples for routine 
tuberculosis investigations available at the study hospital; 
the appendix provides further details of the tests available 
at each hospital.
Tuberculosis screening samples (ie, sputum or urine, 
or both) were processed according to study group 
allocation by the study laboratory technician, and assays 
were run during office hours and processed as soon as 
possible after arrival of a specimen in the laboratory. In 
both groups, sputum was tested using the Xpert 
MTB/RIF assay (Xpert; Cepheid, Sunnyvale, CA, USA). 
In the standard-of-care group, urine samples were not 
tested for tuberculosis. In the intervention group, 
60 µL of unconcentrated urine was tested with the 
Alere Determine TB-LAM Ag assay (TB-LAM; Alere, 
Waltham, MA, USA) as per the manufacturer’s 
instructions, and 40–50 mL of urine was concentrated 
by centrifugation for testing with Xpert. Urine Xpert 
and TB-LAM were processed simultaneously. We 
deemed TB-LAM positive using the grade 1 cutoff on 
the manufacturer’s post-2014 reference card, which was 
referred to as the grade 2 cutoff before 2014. The 
appendix provides further details of the laboratory 
methods used in this study.
Once all the tuberculosis specimens received had been 
processed, tuberculosis screening results were reported 
to the attending clinical team as positive, negative, or not 
done to maintain masking, with neither study group 
nor individual test results communicated to attending 
clinical or study teams. Rifampicin resistance results, if 
available, were also reported (appendix). Clinical manage-
ment, including tuberculosis treatment decisions and 
management of antiretroviral therapy (ART), relied on 
the attending clinical team according to local and national 
guidelines and was independent of study nurses, 
clinicians, or investigators.
The study team documented patients’ clinical events 
during hospital admission, including but not limited to 
tuberculosis investigations and diagnosis, commence-
ment of tuberculosis treatment and any side-effects, 
management of HIV (including stopping or starting 
ART), and discharge or death. Follow-up at 56 days for 
those discharged from hospital alive was done in person 
by outpatient attendance. Those who did not attend were 
contacted by telephone or a home visit, or both, with 
interview of next of kin to establish vital status if required.
Outcomes
The primary outcome was the cumulative risk of all-cause 
mortality at 56 days from enrolment. Subgroup analysis 
for the primary outcome was prespecified in populations 
with higher risk of tuberculosis, mortality, or both (ie, low 
baseline CD4 cell count, low haemoglobin, or clinical 
suspicion for tuberculosis); and by study site and calendar 
time. Secondary outcomes were time to mortality, 
proportions of patients with microbiologically confirmed 
tuberculosis and clinically diagnosed tuberculosis, time 
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from randomisation to tuberculosis diagnosis and to start 
of tuberculosis treatment, time from tuberculosis 
diagnosis to treatment initiation, prescription of 
antimicrobials, ART initiation (if ART naive at hospital 
admission), duration of hospitalisation, and hospital 
readmission events.
Microbiologically confirmed tuberculosis was defined 
as one or more positive specimens for acid fast bacilli, 
Xpert, mycobacterial culture, or TB-LAM. Clinically 
diagnosed tuberculosis was defined by the decision to 
treat for tuberculosis in the absence of microbiological 
confirmation. Patients with any tuberculosis diagnosis 
(microbiologically confirmed or clinically diagnosed) 
were also reported. We recorded for all patients whether 
tuberculosis was included in the admitting differential 
diagnoses by attending clinicians, referred to as clinically 
suspected tuberculosis.
Statistical analysis
The sample size calculation was based on the assumption 
that 56-day mortality risk would be 25% in the standard-
of-care group, and loss to follow-up would be 10% or less. 
We therefore calculated that enrolling 1300 patients 
per group would provide at least 80% power to detect 
a 5% absolute mortality reduction in the intervention 
group, with a two-sided type 1 error of 5% (appendix).
We used an intention-to-treat principle for all our 
analyses, including all eligible patients that were randomly 
assigned. For the primary outcome, we calculated a risk 
difference with 95% CIs for mortality at 56 days comparing 
the standard-of-care group with the inter vention group 
with the following: using a generalised linear model with 
identity link function and binomial family, adjusting for 
study site, using a fixed effect, and assuming participants 
lost to follow-up had not died. An odds ratio adjusted for 
site with 95% CIs was also calculated using logistic 
regression. Prespecified subgroup analyses were done for 
the primary outcome. These subgroups were study site 
(Malawi or South Africa), baseline CD4 counts (<100 cells 
per μL or ≥100 cells per μL), severe anaemia (haemoglobin 
<8 g/dL or ≥8 g/dL), whether tuberculosis was clinically 
suspected at admission, and calendar time (by 6 monthly 
intervals from Oct 1, 2015, to Sep 30, 2017). A sensitivity 
analysis was also done assuming all losses to follow-up 
had died.
Secondary outcomes were compared between the study 
groups using adjusted risk difference and adjusted odds 
ratio (aOR) for binary outcomes, Cox proportional hazards 
regression for time-to-event outcomes, and Kaplan-Meier 
curves for time to mortality. 95% CI were calculated for all 
analyses. In exploratory post-hoc analyses, tuberculosis 
diagnoses were also compared between study groups 
using the same subgroups as the primary outcome (study 
site, baseline CD4 cell count, severe anaemia, and 
clinically suspected tuberculosis) to investigate whether 
the absence of mortality benefit was accompanied by a 
lack of difference in tuberculosis diagnosis. Diagnostic 
yields of urine-based tuberculosis tests were calculated 
post hoc as a proportion of all microbiologically confirmed 
tuberculosis to better understand the respective 
contributions of TB-LAM and urine Xpert.
We did all the analyses using SAS (version 9.4). This 
study is registered with the ISRCTN registry, number 
ISRCTN71603869.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
Figure 1: Trial profile
Patients could have more than one reason for exclusion. Data stratified by site are shown in the appendix.
1300 standard-of-care group 
13 excluded
12 recruited twice
1 HIV negative
1287 included in intention-to-treat analysis 
12 444 adult medical admissions  
7310 excluded
5934 HIV negative
1376 HIV status unknown
346 not screened
41 died or discharged before screening
285 already enrolled in STAMP trial
20 unknown reason
2188 excluded
1928 not eligible
94 aged <18 years
654 unable to give consent
346 live outside study area
920 taking tuberculosis treatment
70 taking isoniazid preventative 
therapy
109 admitted >48h
260 eligible but did not consent
5134 HIV-positive medical admissions 
4788 screened for eligibility 
2600 randomly assigned
1300 intervention group 
13 excluded
13 recruited twice
1287 included in intention-to-treat analysis 
Endpoints
272 died
13 lost to follow-up
1002 completed study and are alive
Endpoints
235 died
14 lost to follow-up
2 withdrew consent
1036 completed study and are alive
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the report. The corresponding author had full access to all 
the data in the study and had final responsibility for the 
decision to submit for publication.
Results
Between Oct 26, 2015, and Sept 19, 2017, we screened 
4788 HIV-positive adult medical admissions. Of these 
admissions, 1928 (40%) patients were ineligible, 
260 (5%) did not provide consent to participate, and 
2600 (54%) were randomly assigned to the study groups 
(n=1300 for each group; figure 1). The appendix shows 
those who were excluded by site. 26 patients were 
excluded after randomisation because of ineligibility, 
leaving 2574 in the final intention-to-treat analysis 
(n=1287 in each group). 27 (1%) of 2574 patients were 
lost to follow-up at 56 days after hospital discharge 
(figure 1).
Baseline characteristics were balanced between the study 
groups (table; appendix). Mean age was 39·6 years 
(SD 11·7 years) and 1461 (57%) of 2574 participants were 
women. 2168 (84%) patients already knew their HIV 
diagnosis before admission, of whom 1861 (86%) were 
currently taking ART. Median CD4 count was 227 cells 
per μL (IQR 79–436), 748 (29%) of 2574 patients had a CD4 
count of less than 100 cells per μL, and 587 (23%) had 
severe anaemia (haemoglobin <8 g/dL). 1332 (52%) patients 
reported a cough, 2316 (90%) had one or more WHO 
tuberculosis symptoms (ie, cough, fever, weight loss, or 
night sweats), and 996 (39%) were clinically suspected of 
tuberculosis at admission. Differences between sites 
included higher ART coverage, fewer patients reporting 
cough, fewer able to expectorate sputum, and fewer having 
clinically suspected tuberculosis at admission in Malawi 
than in South Africa (table).
By 56 days, 507 (20%) of 2574 patients had died: 
272 (21%) of 1287 in the standard-of-care group and 
235 (18%) of 1287 in the intervention group, giving an 
adjusted risk difference of –2·8% (95% CI –5·8 to 0·3; 
p=0·074; figure 2). The aOR for mortality in the inter-
vention group compared with the standard-of-care group 
was 0·83 (95% CI 0·69–1·01; p=0·068; appendix). 
Mortality in the intervention group was significantly lower 
than in the standard-of-care group for the three prespecified 
high-risk subgroups: adjusted risk difference –7·1% 
(95% CI –13·7 to –0·4) in patients with base line CD4 
counts less than 100 cells per µL, –9·0% (–16·6 to –1·3) in 
patients with severe anaemia, and –5·7% (–10·9 to –0·5) in 
patients with clinically suspected tuberculosis at admission 
(figure 2). p values for interaction between the subgroup 
and study group are reported in figure 2. 1567 (61%) of 
2574 patients were in one or more high-risk subgroups 
(low CD4 count, severe anaemia, or clinically suspected 
tuberculosis). Sensitivity analysis assuming losses to 
follow-up had died did not alter overall or subgroup 
mortality risk differences (appendix).
Overall, 36 patients would need to be screened with 
the study intervention (ie, TB-LAM and urine Xpert) 
to prevent one death (appendix). Median duration of 
hospital stay was 6 days (IQR 2–11), and did not differ 
between the two groups (appendix). Although 273 (54%) of 
507 deaths occurred during hospital admission, overall 
and high-risk subgroup survival curves did not sub-
stantially diverge until after day 21 (figure 3). Among 
patients discharged alive from hospital, 134 (12%) of 
1146 patients died in the standard-of-care group and 
100 (9%) of 1150 died in the intervention group. In time-
to-mortality analysis, the adjusted hazard ratio (aHR) for 
intervention compared with standard of care was 
0·86 (95% CI 0·72–1·02; p=0·086; figure 3A).
Of the study’s tuberculosis screening samples at 
baseline, urine was provided by 2548 (99%) of 
2574 patients, whereas only 1464 (57%) produced 
sputum (518 [39%] of 1316 in Malawi and 946 [75%] of 
1258 in South Africa). Chest radiographs as part of 
Standard-of-care 
group (n=1287)
Intervention 
group (n=1287)
Malawi 
(n=1316)
South Africa 
(n=1258)
Age (years) 39·6 (11·9) 39·7 (11·6) 40·1 (11·7) 39·1 (11·7)
Sex
Women 734 (57%) 727 (56%) 829 (63%) 632 (50%)
Men 553 (43%) 560 (44%) 487 (37%) 626 (50%)
New HIV diagnosis 212 (16%) 194 (15%) 208 (16%) 198 (16%)
ART status*
Never 93 (9%) 121 (11%) 57 (5%) 157 (15%)
Currently taking 935 (87%) 926 (85%) 1021 (92%) 840 (79%)
Interrupted 47 (4%) 46 (4%) 30 (3%) 63 (6%)
Time on ART (years)† 3·0 (0·7–6·7) 3·0 (0·8–6·7) 3·4 (0·8–7·4) 2·6 (0·6–5·8)
TB symptoms reported
Cough 681 (53%) 651 (51%) 611 (46%) 721 (57%)
Fever 747 (58%) 753 (59%) 761 (58%) 739 (59%)
Night sweats‡ 540 (42%) 497 (39%) 488 (37%) 549 (44%)
Weight loss‡ 875 (68%) 906 (70%) 863 (66%) 918 (73%)
Any WHO TB symptom 1164 (90%) 1152 (90%) 1187 (90%) 1129 (90%)
Clinically suspected TB§ 495 (38%) 501 (39%) 353 (27%) 643 (51%)
Previous TB treatment 309 (24%) 335 (26%) 202 (15%) 442 (35%)
Body-mass index (kg/m²) 21·7 (5·8) 21·6 (5·8) 20·0 (4·1) 23·3 (6·7)
Morbidity at admission
WHO danger sign¶ 275 (21%) 277 (22%) 337 (26%) 215 (17%)
Karnofsky score 60 (50–70) 60 (50–70) 60 (50–70) 60 (50–70)
CD4 cell count§
Median (cells per µL) 222 (80–436) 231 (78–438) 219 (86–431) 236 (70–445)
<100 cells per µL 377 (29%) 371 (29%) 365 (28%) 383 (30%)
Haemoglobin||
Median (g/dL) 10·4 (8·1–12·9) 10·8 (8·3–12·7) 10·4 (7·8–12·4) 113 (8·8–13·1)
<8 g/dL 298 (23%) 289 (22%) 355 (27%) 232 (18%)
Data are mean (SD), n (%), or median (IQR). TB symptoms are reported if present for any duration. ART=antiretroviral 
therapy. TB=tuberculosis. *ART status denominator is the number of patients with a known HIV diagnosis (n=1075 for 
standard-of-care group and n=1093 for intervention group). †Missing data for 26 patients in Malawi and 26 in South 
Africa. ‡Missing data for one patient in South Africa. §Missing data for three patients in Malawi and six in South Africa. 
¶WHO danger signs are one or more of the following: heart rate more than 120 beats per minute, respiratory rate more 
than 30 breaths per minute, temperature more than 39°C, or being unable to walk unaided. ||Missing data for five patients 
in South Africa. 
Table: Patient characteristics at enrolment by study group and country
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routine care were taken in 1231 (48%) of 2574 patients 
during in patient stay (300 [23%] of 1316 in Malawi and 
931 [74%] of 1258 in South Africa; appendix). Overall, 
tuberculosis was diagnosed during hospital admission 
in 474 (18%) of 2574 patients, with 282 (22%) diagnoses 
in the intervention group and 192 (15%) in the standard-
of-care group (appendix). The adjusted risk difference 
for tuberculosis diagnosis between the two groups was 
7·3% (95% CI 4·4–10·2; p<0·0001). The intervention 
group also had more microbiologically confirmed tuber-
cu losis diagnoses than the standard-of-care group 
(210 [16%] of 1287 vs 85 [7%] of 1287; adjusted risk 
difference 9·9% [95% CI 7·5–12·4]; p<0·0001) and 
fewer clinically diagnosed tuberculosis (77 [6%] vs 
114 [9%]; adjusted risk difference –3·1% [–4·9 to –1·4]; 
p=0·0004; figure 2). 14 patients would need to be 
screened with the study intervention to prevent one 
missed tuberculosis diagnosis (appendix).
Time from randomisation to tuberculosis diagnosis was 
marginally shorter in the intervention group than in the 
Figure 2: Primary outcome and predefined subgroup analyses (A), and secondary outcomes (B)
All analyses are adjusted for study site. (A) The primary outcome is mortality at 56 days after randomisation. Risk differences are the risk in the intervention group 
minus the risk in the standard-of-care group. (B) Secondary outcomes are measured at the end of hospital admission except for those who started ART, which is 
measured at 56 days. Antibacterial treatment excludes anti-TB medications. ART=antiretroviral therapy. *Interaction between study group and subgroup.
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standard-of-care group (median 0 days [IQR 0–1] vs 
1 day [0–6]; appendix). 450 patients were started on 
tuberculosis treatment during admission, 268 in the 
intervention group and 182 in the standard-of-care group 
(aHR 1·56, 95% CI 1·29–1·88; p<0·0001; appendix). Time 
from diagnosis to tuberculosis treatment was universally 
short (median of 1 day, IQR 0–1) and was similar in both 
groups. Adverse events related to tuberculosis treatment 
were similar in both groups; the appendix summarises 
these adverse events. Antibacterial treatment and ART 
initiation did not differ by group (figure 2), although time 
to ART initiation was shorter in the intervention group 
than in the standard-of-care group (appendix). Of the 
24 patients diagnosed with tuberculosis but not started on 
Figure 3: Time to 56-day mortality overall and stratified by high-risk subgroups
All aHRs were adjusted for study site. (A) Survival analysis over 56 days in the standard-of-care group and intervention group. (B) Survival analysis stratified by 
CD4 counts less than 100 cells per µL in both groups. (C) Survival analysis stratified by CD4 counts of 100 cells per µL or more in both groups. (D) Survival analysis 
stratified by haemoglobin of less than 8 g/dL in both groups. (E) Survival analysis stratified by haemoglobin of 8 g/dL or more in both groups. aHR=adjusted hazard ratio.
Number at risk
Standard-of-care group
Intervention group
0 7 14 21 28 35 42 49 56
1287
1287
1218
1220
1162
1160
1126
1124
1095
1103
1069
1082
1046
1071
1024
1059
1004
1040
0
10
20
30
40
100
Pr
ob
ab
ili
ty
 o
f d
ea
th
 (%
)
A
Standard-of-care group
Intervention group
Number at risk
Standard-of-care group
Intervention group
0 7 14 21 28 35 42 49 56
373
371
338
347
308
319
294
298
276
285
264
277
253
272
243
267
236
261
Pr
ob
ab
ili
ty
 o
f d
ea
th
 (%
)
E
0 7 14 21 28 35 42 49 56
7 14 21 28 35 42 49 56 0 7 14 21 28 35 42 49 56
897
904
867
861
841
829
819
814
806
807
793
794
782
788
771
781
758
767
Number at risk
Standard-of-care group
Intervention group
0
298
289
273
263
249
236
234
223
222
219
209
212
198
210
188
206
180
200
Follow-up (days)
0
10
20
30
40
50
60
70
80
90
100
Pr
ob
ab
ili
ty
 o
f d
ea
th
 (%
)
D
987
995
942
953
910
920
889
898
871
881
857
866
845
858
833
849
821
836
Follow-up (days)
aHR 0·86 (95% CI 0·72–1·02); p=0·086
aHR 0·77 (95% CI 0·60–1·00); p=0·047 aHR 0·97 (95% CI 0·76–1·24); p=0·83
aHR 0·76 (95% CI 0·57–1·00); p=0·049 aHR 0·94 (95% CI 0·75–1·18); p=0·59
C
0
10
20
30
40
50
60
70
80
90
50
60
70
80
90
100
B
Articles
www.thelancet.com   Vol 392   July 28, 2018 299
treatment during hospital admission, ten (42%) had died 
and 14 (58%) had been prematurely discharged. Only 
27 other patients were started on tuberculosis treatment 
between discharge and day 56, with no difference between 
groups (appendix). Hospital readmission, losses to follow-
up, adverse events (tuberculosis treatment discontinuation 
and side-effects), and rifampicin resistance detection did 
not differ between groups (appendix).
In post-hoc exploratory analyses, the increases in 
tuberculosis diagnoses in the intervention group versus 
the standard-of-care group were not confined to high-risk 
subgroups, unlike mortality, with an adjusted absolute risk 
increase of 7·0% (95% CI 4·1–10·0) in tuberculosis 
diagnoses in patients with CD4 counts of 100 cells per µL 
or more, and 8·0% (5·0–11·1) in those not clinically 
suspected of tuberculosis at admission (appendix). 
Increased tuberculosis diagnoses were more pronounced 
in Malawi than South Africa, although there was no 
evidence for an interaction between group and country 
(p=0·19). The largest increase in tuberculosis diagnoses in 
the intervention group was in the severe anaemia group, 
with an adjusted risk increase of 18·6% (95% CI 11·5–25·6; 
interaction p=0·0002). There were 93 extra patients on 
treatment for confirmed tuberculosis who were discharged 
alive and 34 fewer post-discharge deaths in the intervention 
group than in the standard-of-care group. Sputum Xpert 
diagnosed a similar number of patients with tuberculosis 
in both groups (appendix). In the intervention group, 
TB-LAM provided the highest diagnostic yield (158 [75%] of 
210 patients with microbiologically confirmed tubercu-
losis), compared with 74 (35%) patients positive with urine 
Xpert and 85 (40%) positive with sputum Xpert (appendix). 
The incremental diagnostic yield from urine Xpert as the 
only positive assay was only 13 (6%) patients, compared 
with 87 (41%) patients from TB-LAM and 30 (14%) patients 
from sputum Xpert.
Discussion
Although the 56-day all-cause mortality showed no 
significant differences between the standard-of-care and 
intervention groups, the addition of urine-based tubercu-
losis screening using TB-LAM and Xpert to sputum-
based screening in all HIV-positive medical inpatients 
significantly reduced mortality at 56 days in prespecified 
high-risk subgroups, and substantially increased tubercu-
losis diagnoses and treatment across all patients. Fewer 
patients were on tuberculosis treatment at discharge in the 
standard-of-care group than in the intervention group, and 
more patients died after discharge, suggesting discharge 
with undiagnosed and untreated active tuberculosis as the 
main underlying mechanism. For every ten extra patients 
with confirmed tuberculosis discharged on treatment in 
the intervention group, there were 3·7 fewer deaths after 
discharge, supporting high individual risk of rapid 
progression to death in undiagnosed HIV-associated 
tuberculosis that could have been detected and treated 
through urine-based screening.
Morbidity and mortality from HIV-associated tuber-
culosis are slowly decreasing in Africa, mainly reflecting 
the expansion of HIV diagnosis and ART programmes 
rather than tuberculosis-specific diagnostic and pre-
vention interventions.18,19 Although these trends are 
encouraging, we found disturbingly high risk of death or 
microbiologically confirmed tuberculosis, or both, within 
56 days of admission, despite high ART coverage and 
median CD4 cell count. We report substantial mortality 
reductions from urine-based tuberculosis screening in 
prespecified high-risk subgroups, consistent with current 
recommendations for diagnostic LAM testing, but no 
significant effect on overall mortality at 56 days between 
groups (adjusted risk difference –2·8%, 95% CI 
–5·8 to 0·3). However, our study was underpowered to 
detect small (<5%) absolute reductions in mortality at 
56 days.
Our findings are consistent with the 4% (95% CI 1–7) 
mortality reduction in HIV-positive inpatients with 
clinic ally suspected tuberculosis reported from a diag-
nostic (not screening) randomised trial of urine LAM 
testing.20 The participant profile in the diagnostic trial 
differed notably from this study, with lower ART coverage 
and CD4 counts (median 84 cells per µL vs 227 cells 
per µL), and a greater proportion of participants had 
tuberculosis (intervention groups: 51·6% vs 21·8%), 
reflecting different inclusion criteria (clinical suspicion 
of tuberculosis compared with an unselected population 
in our STAMP trial), as well as underlying population 
trends in ART coverage. Early survival benefit from 
these two trials underscores the fulminant course of 
undiagnosed tuberculosis in highly immunosuppressed 
patients, and the higher yield of urinary diagnostics 
and difficulty diagnosing tuberculosis among groups of 
hospitalised HIV-positive patients by other means.13,15
Uniquely, STAMP recruited considerable numbers of 
less immunosuppressed or critically ill patients who fall 
outside current recommendations for urinary tuber-
culosis diagnostic assays.21 We show differences between 
groups in tuberculosis diagnosis, although with a 
corresponding mortality benefit only for predefined high-
risk groups (ie, low CD4 cell counts, low haemoglobin, 
or clinically suspected tuberculosis). The absence of 
detectable survival benefit in patients with less profound 
immunosuppression might then simply reflect a slower 
time-course if median survival following discharge with 
undiagnosed tuberculosis is considerably longer than 
56 days. If so, increases in tuberculosis treatment through 
early urine-based diagnosis will still have averted months 
of morbidity and contributed to reduced transmission, 
particularly in health-care settings.22 An alternative 
explanation is a higher proportion of false-positive urinary 
screening results in patients with CD4 counts of 100 cells 
per µL or more, which we consider unlikely given high 
specificity (≥99%) shown else where.14,15,23
Better clinical acumen and alternative investigations 
such as radiology leading to early empirical tuberculosis 
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treatment can mitigate the effect of new diagnostic tests, 
as observed in relatively well resourced inpatient and 
outpatient settings, for example in South Africa.24 We saw 
little evidence of this effect for urine-based screening in 
either Malawi or South Africa in our STAMP trial, and 
also showed no difference in routine management 
between groups, for instance in the use of broad-spectrum 
antibiotics to treat presumed bacterial infections. Both 
urine LAM (point-of-care lateral flow assay) and Xpert 
(approximately 2 h after urine centrifugation) are rapid, 
as was initiation of tuberculosis treatment in this trial, 
which are crucial to affect mortality and potentially 
transmission.
The least costly and easiest urine test (TB-LAM) had 
major incremental diagnostic benefit in this trial, with 
urine Xpert (which is more complex because of urine 
centrifugation) contributing few additional diagnoses. 
This finding argues for the use of LAM alone as the 
urinary diagnostic for screening, an approach supported 
by STAMP’s cost-effectiveness projections being reported 
separately.25 Urine Xpert might still have a place alongside 
other diagnostic modalities for urine LAM-negative 
patients with high clinical suspicion for tuberculosis.16 
Sputum Xpert is already a recommended standard of 
care for HIV-positive individuals with tuberculosis 
symptoms (although not uniformly implemented), and 
was included for all patients able to expectorate in both 
trial groups.9 Our data support this approach, because 
sputum provided the only microbiological diagnosis for 
14% of patients with tuberculosis in the intervention 
group.
Despite the qualified mortality benefits, we consider 
our results to be supportive of routine implementation of 
systematic screening with urinary LAM, in addition to 
sputum Xpert, for all HIV-positive inpatients, given that 
LAM screening provides a substantial increase in 
diagnosis of a treatable but frequently fatal condition 
(disseminated tuberculosis). Systematic screening on 
admission to hospital is a simple strategy that avoids 
expense and delay from identifying high-risk groups 
(including by CD4 count testing, which might not be 
routinely available).26 Tuberculosis symptoms were 
present in 90% of patients yet only 39% were considered 
to have tuberculosis by clinicians, who would have 
missed a substantial number of diagnoses. Notably, 
61% of inpatients in STAMP were in one or more high-
risk groups with a mortality benefit. Pronounced 
differences in short-term mortality and underlying 
prevalence of disseminated tuberculosis between HIV-
positive inpatients and outpatients also means that 
current WHO policy (specific recommendation against 
use for screening, with use of TB-LAM indicated only for 
diagnostic purposes in patients with tuberculosis 
symptoms and CD4 counts <100 cells per µL or signs of 
severe illness) should remain in use for outpatients.21
There are limitations to our study. In sample size 
calculations, we assumed a higher mortality and burden 
of tuberculosis than we observed, possibly because of the 
success of ART scale-up. We did not include a culture 
reference standard, as this reference is neither standard 
of care nor routinely available in Malawi, and would have 
presented ethical dilemmas or affected generalisability. 
Relatively few participants in Malawi produced sputum. 
This difficulty in expectorating sputum is, however, 
typical of unselected HIV-positive outpatient and 
inpatient cohorts in resource-constrained settings, and is 
a major barrier to implementation of sputum-based 
tuberculosis screening.15,27 Generalising the true effect of 
this intervention might be compromised by un-
characteristically prompt specimen collection and results 
reporting in the study setting, and masking of routine 
clinicians to exactly which tests had been done might 
have altered their clinical decision making.28 Conversely, 
because both urine assays were run in a laboratory, we 
might have underestimated the effect on outcomes from 
TB-LAM if used at the bedside with faster turnaround 
times. Patients excluded because of their inability to 
consent will have introduced bias to the study towards the 
less critically ill, potentially affecting generalisability.
In conclusion, we report a survival benefit from 
urine-based tuberculosis screening of HIV-positive hos-
pital admissions in high-risk subgroups, and a broader 
benefit through substantially increased predischarge 
tuber culosis diagnosis and treatment in all patients. 
Tuberculosis screening with urine-LAM lateral flow 
assays is inexpensive and easily implementable, requiring 
minimal infrastructure and training. Tuberculosis diag-
nosed through urine-based screening was complemen tary 
to tuberculosis diagnosed through standard clinical 
investigations in both countries, with inferred higher risk 
of discharge with undiagnosed tuberculosis in the 
standard-of-care group than in the intervention group. 
Anticipated improvements in analytical performance of 
next-generation LAM assays might add to the diagnostic 
yield from systematic urine screening.29 Current WHO 
guidelines on the diagnostic use of TB-LAM in HIV-
positive inpatients have been insufficient to motivate 
widespread implementation within African hospitals.30 
These results support changes to current policy and 
guidelines for routine inclusion of urine-based tuberculosis 
screening using TB-LAM in a package of interventions for 
HIV-positive patients admitted to hospital in high-burden 
settings, aiming to reduce short-term morbidity and 
mortality.31–33 Such new strategies need to be urgently 
implemented to achieve WHO’s End TB Strategy targets 
of a 75% reduction in tuberculosis mortality by 2025.
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